TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35487105

Group type: EXPERIMENTAL
Intervention: Results communicated by postal letter
Number of subjects: 1900
Study: 35487256

Group type: EXPERIMENTAL
Intervention: MeMed BV® and MeMed Key®
Number of subjects: 0
Study: 35487387

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 35487538

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35487718

Group type: EXPERIMENTAL
Intervention: Liquid biopsies (peripheral blood and urine samples) collected every 6 or 12 months for 11 years, including detection of circulating tumour cells, circulating tumour DNA (ctDNA), exosomal micro-RNA (miRNA), miRNA in Tumour Educated Platelet and metabolomic profiles.
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) collected annually, including 10 PROM questionnaires.
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Control group of 200 women without cancer aged 25-70 years providing the same data.
Number of subjects: 1455
Study: 35487733

Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as the concomitant use of five or more medications, excluding vitamins or dietary supplements)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Greater BMI
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Increased number of comorbidities
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: City of residence (Coimbra)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: City of residence (Geneva)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: City of residence (Toulouse)
Number of subjects: 2157
Study: 35487735

Group type: EXPERIMENTAL
Intervention: Exposure to any traumatic event
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Exposure to non-partner rape
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 677
Study: 35487745

Group type: EXPERIMENTAL
Intervention: High physical activity level
Number of subjects: 452
Study: 35487814

Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (9vHPV)
Number of subjects: 1990
Study: 35487845

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC trastuzumab) administered every 3 weeks for 18 cycles as adjuvant therapy
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with no chemotherapy
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with concurrent chemotherapy
Number of subjects: 2573

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with sequential chemotherapy
Number of subjects: 2573
Study: 35487894

Group type: EXPERIMENTAL
Intervention: Wheelchair-modified ergometer rowing exercise (REMW), 3 times weekly for up to 30 minutes per session
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wheelchair-modified ergometer rowing exercise (REMW)
Number of subjects: 8
Study: 35488054

Group type: EXPERIMENTAL
Intervention: Aerobic fitness
Number of subjects: 0
Study: 35488127

Group type: EXPERIMENTAL
Intervention: Early AF ablation
Number of subjects: 25963

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 25963
Study: 35488129

Group type: EXPERIMENTAL
Intervention: STRONG contractions of the hand/wrist
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: WEAK contractions of the hand/wrist
Number of subjects: 14

Group type: COMPARATOR
Intervention: CONTROL condition
Number of subjects: 14
Study: 35488256

Group type: EXPERIMENTAL
Intervention: Cleaning workers (hospital and university groups)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cleaning workers (hospital and housekeeper groups)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cleaning workers
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: University group
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cleaning workers (overall)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Hospital cleaning workers
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Length of time performing cleaning work
Number of subjects: 167
Study: 35488261

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 72
Study: 35488283

Group type: EXPERIMENTAL
Intervention: tPA gene expression
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: uPA gene expression
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PAI-1 gene expression
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PAI-2 gene expression
Number of subjects: 33
Study: 35488295

Group type: EXPERIMENTAL
Intervention: EPIO intervention (app-based cognitive-behavioral pain self-management program)
Number of subjects: 50
Study: 35488337

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids plus long-acting beta agonists
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: Spirometry grading
Number of subjects: 4978

Group type: EXPERIMENTAL
Intervention: COPD classification
Number of subjects: 4978
Study: 35488422

Group type: EXPERIMENTAL
Intervention: Controlled lockdown with social distancing (study group)
Number of subjects: 5800000

Group type: COMPARATOR
Intervention: No controlled lockdown and social distancing (reference group)
Number of subjects: 5800000
Study: 35488717

Group type: EXPERIMENTAL
Intervention: Homecare (yes)
Number of subjects: 406

Group type: COMPARATOR
Intervention: No homecare (no)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Readmission (yes)
Number of subjects: 406

Group type: COMPARATOR
Intervention: No readmission (no)
Number of subjects: 406
Study: 35488718

Group type: EXPERIMENTAL
Intervention: Gene expression score of ENOX1
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Gene expression scores of MAN2A1 and PCGF3
Number of subjects: 425
Study: 35488900

Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg once daily) + azacitidine
Number of subjects: 72
Study: 35488938

Group type: EXPERIMENTAL
Intervention: Screening by Professionals (ProfScreen)
Number of subjects: 4172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4172

Group type: EXPERIMENTAL
Intervention: Attending the ProfScreen interview
Number of subjects: 4172
Study: 35489133

Group type: EXPERIMENTAL
Intervention: Low blood pressure (systolic BP ≤ 110 mm Hg and/or diastolic BP ≤ 70 mm Hg)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: High blood pressure (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug use
Number of subjects: 1394
Study: 35489233

Group type: EXPERIMENTAL
Intervention: Regorafenib (REGO) 160 mg/day for 21 days of a 28-day cycle
Number of subjects: 55
Study: 35489377

Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (5 mg)
Number of subjects: 181
Study: 35490124

Group type: EXPERIMENTAL
Intervention: Performed PCI
Number of subjects: 400

Group type: COMPARATOR
Intervention: Deferred PCI
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Performed PCI in preserved CFR cohort
Number of subjects: 400

Group type: COMPARATOR
Intervention: Deferred PCI in preserved CFR cohort
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Performed PCI in depressed CFR cohort
Number of subjects: 400

Group type: COMPARATOR
Intervention: Deferred PCI in depressed CFR cohort
Number of subjects: 400
Study: 35490339

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy-pacemaker (CRT-P)
Number of subjects: 1738

Group type: COMPARATOR
Intervention: Control group (no CRT-P)
Number of subjects: 1738
Study: 35490596

Group type: EXPERIMENTAL
Intervention: Higher BMI and BP in all children
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Every unit increase in SBP
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Every unit increase in DBP
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Black SA children
Number of subjects: 2100
Study: 35490915

Group type: EXPERIMENTAL
Intervention: Brain structural components associated with low mid-life performance across multiple cognitive domains, decline in reasoning, but maintenance of fluency abilities.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Brain structural components associated with low mid-life performance in fluency and memory, but retention of multiple abilities.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Expression of latent variables predicting future cognition.
Number of subjects: 3
Study: 35491417

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 30
Study: 35491419

Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 109

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 109
Study: 35491421

Group type: EXPERIMENTAL
Intervention: Ubiquitous priority infections diagnosed in participants (total 452, 23.5%)
Number of subjects: 1922

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for S. Typhi
Number of subjects: 1922

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) for leptospirosis
Number of subjects: 1922
Study: 35491432

Group type: EXPERIMENTAL
Intervention: Anlotinib plus TQB2450
Number of subjects: 66
Study: 35491481

Group type: EXPERIMENTAL
Intervention: Iliac artery EVT
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: TASC D
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Technical success rate
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Predictors for TLR
Number of subjects: 1364
Study: 35491482

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 3075

Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 3075
Study: 35491511

Group type: EXPERIMENTAL
Intervention: STAR-OX40 T-cell therapy
Number of subjects: 18
Study: 35491519

Group type: EXPERIMENTAL
Intervention: Low-dose glibenclamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35491674

Group type: EXPERIMENTAL
Intervention: High dietary sugar intake
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low dietary sugar intake
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sucrose ingestion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Healthy weight
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 68
Study: 35491738

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical ivermectin
Number of subjects: 0
Study: 35491783

Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cooperation with other healthcare providers
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nursing care
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Higher number of tasks
Number of subjects: 183
Study: 35492244

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light (NfL) levels in FTD syndromes and presymptomatic mutation carriers
Number of subjects: 0
Study: 35492329

Group type: EXPERIMENTAL
Intervention: Low Fat-Free Muscle Index (L-FFMI)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Large Total Cross-Sectional Spontaneous Portosystemic Shunt Area (L-TSA)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Simultaneous presence of L-FFMI and L-TSA
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: L-FFMI
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: L-TSA
Number of subjects: 156
Study: 35492333

Group type: EXPERIMENTAL
Intervention: Rheopheresis (RheoP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35492338

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 22
Study: 35492586

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35492873

Group type: EXPERIMENTAL
Intervention: AXL targeting intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35492875

Group type: EXPERIMENTAL
Intervention: CCL18 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockade of CCR8
Number of subjects: 0
Study: 35493124

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (700 mg) and Etesevimab (1400 mg)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and Etesevimab
Number of subjects: 769
Study: 35493516

Group type: EXPERIMENTAL
Intervention: PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle
Number of subjects: 0
Study: 35493739

Group type: EXPERIMENTAL
Intervention: Microbial samples from the oral cavity, sputum, and ileum of patients with CD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cavity and sputum microbiota
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbiota composition in oral cavity and sputum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbiota architecture in oral cavity, sputum, and ileum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study of microbiota dysbiosis
Number of subjects: 0
Study: 35493925

Group type: EXPERIMENTAL
Intervention: Random Forests (RF) model
Number of subjects: 18209
Study: 35493932

Group type: EXPERIMENTAL
Intervention: BAILAMOS™ Latin dance program
Number of subjects: 333

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 333
Study: 35494168

Group type: EXPERIMENTAL
Intervention: Pectoralis muscle strength in patients with IPF
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pectoralis muscle strength in healthy controls
Number of subjects: 17
Study: 35495025

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 2277

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 2277
Study: 35496758

Group type: EXPERIMENTAL
Intervention: rHIgM22 (0.5 or 2.0 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 35497488

Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) with the Sonata System
Number of subjects: 147
Study: 35497778

Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg subcutaneously (s.c.) monthly for 12 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clazakizumab for >2.5 years in long-term extension (LTE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clazakizumab treatment
Number of subjects: 10
Study: 35497805

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35497806

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 302

Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA)
Number of subjects: 302
Study: 35497990

Group type: EXPERIMENTAL
Intervention: Prognostic assessment and management pathway (intervention group)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 498
Study: 35498010

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 84
Study: 35498017

Group type: EXPERIMENTAL
Intervention: Changes in cardiac symptoms from 3 to 12 months after ACS hospitalization
Number of subjects: 0
Study: 35498050

Group type: EXPERIMENTAL
Intervention: L-Arginine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35498381

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus low-dose apatinib
Number of subjects: 25
Study: 35498781

Group type: EXPERIMENTAL
Intervention: Continuous cerebral tissue oxygen saturation (cStO2) monitoring
Number of subjects: 162
Study: 35499065

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 35499083

Group type: EXPERIMENTAL
Intervention: Hymecromone 1200 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hymecromone 2400 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hymecromone 3600 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hymecromone (all doses combined)
Number of subjects: 26
Study: 35499104

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day, increased to 20 mg/day after 1 week
Number of subjects: 100
Study: 35499468

Group type: EXPERIMENTAL
Intervention: anti-interleukin-1β (IL-1β), anti-IL-6, and anti-tumor necrosis factor α
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Peripheral unmethylated INS DNA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postmortem pancreatic tissues
Number of subjects: 10
Study: 35499706

Group type: EXPERIMENTAL
Intervention: DLG2 overexpression in colon cancer cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DLG2 silencing in THP1 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 treatment on bystander COLO205 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restoration of DLG2 to the colon
Number of subjects: 0
Study: 35499827

Group type: EXPERIMENTAL
Intervention: Nonoperative management with antibiotics
Number of subjects: 370
Study: 35500016

Group type: EXPERIMENTAL
Intervention: Bexmarilimab (humanized IgG4 antibody against Clever-1)
Number of subjects: 0
Study: 35500125

Group type: EXPERIMENTAL
Intervention: NS7CAR T cells
Number of subjects: 20
Study: 35500223

Group type: EXPERIMENTAL
Intervention: Metformin for 6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study: 35500404

Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m with prophylactic pegfilgrastim
Number of subjects: 28
Study: 35500434

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 197
Study: 35500613

Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (antepartum)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (postpartum)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Transient elastography in healthy controls (antepartum)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Transient elastography in healthy controls (postpartum)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (postpartum) with severe features
Number of subjects: 73
Study: 35501092

Group type: EXPERIMENTAL
Intervention: Lifestyle behaviours and dietary pattern assessment at baseline, including demographic characteristics, medical history, sleep duration and quality, bowel movements, and regular diet.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Follow-up assessments including biochemical measurements, blood pressure, carotid ultrasound, echocardiography, electrocardiography, and cardiac magnetic resonance.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Muscle strength assessment using handgrip dynamometer and MicroFet2 hand-held dynamometer.
Number of subjects: 1500
Study: 35501097

Group type: EXPERIMENTAL
Intervention: Sonoclot (glass beaded) test at admission
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Paired Sonoclot assays at day 1 and 3
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HLE (day 1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Invasive ventilation group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: HLE
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Presence of HLE
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Increased C reactive protein
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Decreased platelet function
Number of subjects: 74
Study: 35501102

Group type: EXPERIMENTAL
Intervention: Plasma (P)-myoglobin and P-creatine phosphokinase analyzed at 6-hourly intervals after admission for 48 hours and after surgical fixation or fasciotomy for 24 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers of muscle cell damage (P-myoglobin and P-creatine phosphokinase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses of biomarkers
Number of subjects: 0
Study: 35501309

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: (2R,6R)-HNK (10 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 35501330

Group type: EXPERIMENTAL
Intervention: Placental DNA methylation and gene expression targets for birthweight GWAS loci
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylation influence on gene expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-trait colocalization
Number of subjects: 0
Study: 35501359

Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction model (Catboost)
Number of subjects: 1568
Study: 35501592

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg single oral dose
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: NUP153 and SVEP1 gene variation
Number of subjects: 175
Study: 35501763

Group type: EXPERIMENTAL
Intervention: Informal caregiver-related factors and psychological burden assessments (WHOQOL-BREF, NCCN-Distress Thermometer, GAD-7, PHQ-9)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Medical records and nurse-reported data
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multivariable regression models
Number of subjects: 240
Study: 35502192

Group type: EXPERIMENTAL
Intervention: Cardiovascular outcomes at 12-month follow-up (including incident AF, stroke, TIA, and myocardial infarction)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Changes in function, depression, anxiety, fatigue, and quality of life
Number of subjects: 1222
Study: 35502515

Group type: EXPERIMENTAL
Intervention: Peer-delivered safety planning
Number of subjects: 31

Group type: COMPARATOR
Intervention: Provider-delivered safety planning
Number of subjects: 31